Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: Pharmacokinetics and correlation with digital perfusion

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Shah, Ami A ^a   Schiopu, Elena ^b   Hummers, Laura K ^a   Wade, Michael ^c   Phillips, Kristine ^b   Anderson, Cynthia ^a   Wise, Robert ^a   Boin, Francesco ^a   Seibold, James R ^d   Wigley, Fredrick ^a   Rollins, Kristan D ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNITED THERAPEUTICS CORPORATION   (United States)

^d Scleroderma Research Consultants LLC   (United States)

Author keywords

ClinicalTrials.gov NCT00848939

Indexed keywords

TREPROSTINIL; ANTIHYPERTENSIVE AGENT; PROSTACYCLIN;

ADULT; ADVERSE EVENT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DIGITAL ISCHEMIA; DIGITAL PERFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; ISCHEMIA; JAW PAIN; LASER DOPPLER FLOWMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; OPEN STUDY; PERFUSION; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SKIN TEMPERATURE; SUSTAINED DRUG RELEASE; SYSTEMIC SCLEROSIS; VOMITING; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPLICATION; FINGER; HALF LIFE TIME; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VASCULARIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; EPOPROSTENOL; FEMALE; FINGERS; HALF-LIFE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 84876181654     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4216     Document Type: Article

References (31)

1. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002;26:194-201
2. Tuder RM, Zaiman AL. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? Am J Respir Cell Mol Biol. 2002;26:171-4
3. Martindale: the complete drug reference. Treprostinil. Micromedex® Healthcare Series. London: Pharmaceutical Press; 2003
4. Vachiery JL, Naeije R. Treprostinil for pulmonary hypertension. Expert Rev Cardiovasc Ther. 2004;2:183-91
5. Remodulin (treprostinil) injection [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2011
6. Medsger Jr TA, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971;75:369-76
7. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore). 1980;59:393-408
8. Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian scleroderma research group registry. Arthritis Care Res (Hoboken). 2011;63:142-9
9. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ. 1989;298:561-4
10. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis. 1991;50:800-4
11. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19:1407-14
12. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger Jr TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, doubleblind study. Ann Intern Med. 1994;120:199-206
13. Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J. 1980;281:1031-4
14. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000953
15. Mohler ER, Klugherz B, Goldman R, Kimmel SE, Wade M, Sehgal CM. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med. 2000;5:231-7
16. Engel G, Rockson SG. Treprostinil for the treatment of severe digital necrosis in systemic sclerosis. Vasc Med. 2005;10:29-32
17. Fernandez B, Strootman D. The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease-a case report and review of literature. Angiology. 2006;57:99-102
18. Berman S, Quick R, Yoder P, Voigt S, Strootman D, Wade M. Treprostinil sodium (Remodulin), a prostacyclin analogue, in the treatment of critical limb ischemia: open-label study. Vascular. 2006;14:142-8
19. Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Derm. 2006;54:880-2
20. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Arthritis Rheum. 1980;23:581-90
21. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin®) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44:209-14
22. White RJ, Allen R, Torres F, Jerjes C, Pulido T, Carroll J, et al. Sustained plasma concentrations of treprostinil following chronic dosing in patients with pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med. 2009;179:A3360
23. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Arneson CP, Hunt TL, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004;44:503-9
24. McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol. 2008;48:19-25
25. Lim A, White RJ, Walker S, Kates J, Laliberte K. The effect of different meal compositions on the pharmacokinetics of treprostinil diethanolamine in healthy volunteers [abstract]. Chest. 2010;138:366A
26. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-93
27. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005;64:1387
28. Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69:1475-8
29. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010;50:829-34
30. Gotzkowsky SK, Laliberte K, Goetz B, Mottola D. Lack of a pharmacokinetic drug interaction following co-administration of UT-15C (treprostinil diethanolamine) SR and Revatio™ (sildenafil citrate) in healthy volunteers [poster]. San Francisco, CA: Presented at: American Thoracic Society; 2007
31. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573-619